IL1B and non-small cell lung carcinoma: In preclinical models of NSCLC, IL-1β blockade exerts an immunogenic effect in the TME via the recruitment and activation of immune effector CD8+ T cells, while reducing peritumoral infiltration by immunosuppressive cells such as MDSCs (15, 37, 38).